14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      m 5C modification of mRNA serves a DNA damage code to promote homologous recombination

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recruitment of DNA repair proteins to DNA damage sites is a critical step for DNA repair. Post-translational modifications of proteins at DNA damage sites serve as DNA damage codes to recruit specific DNA repair factors. Here, we show that mRNA is locally modified by m 5C at sites of DNA damage. The RNA methyltransferase TRDMT1 is recruited to DNA damage sites to promote m 5C induction. Loss of TRDMT1 compromises homologous recombination (HR) and increases cellular sensitivity to DNA double-strand breaks (DSBs). In the absence of TRDMT1, RAD51 and RAD52 fail to localize to sites of reactive oxygen species (ROS)-induced DNA damage. In vitro, RAD52 displays an increased affinity for DNA:RNA hybrids containing m 5C-modified RNA. Loss of TRDMT1 in cancer cells confers sensitivity to PARP inhibitors in vitro and in vivo. These results reveal an unexpected TRDMT1-m 5C axis that promotes HR, suggesting that post-transcriptional modifications of RNA can also serve as DNA damage codes to regulate DNA repair.

          Abstract

          Post-translational modifications of proteins at DNA damage sites can facilitate the recruitment of DNA repair factors. Here, the authors show that mRNA is locally modified with m 5C at sites of DNA damage by the RNA methyltransferase TRDMT1 to promote homologous recombination repair.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

          BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks. We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

            Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Induced ncRNAs Allosterically Modify RNA Binding Proteins in cis to Inhibit Transcription

              With the recent recognition of non-coding RNAs (ncRNAs) flanking many genes1-5, a central issue is to fully understand their potential roles in regulated gene transcription programs, possibly through different mechanisms6-12. Here, we report that an RNA-binding protein, TLS, serves as a key transcriptional regulatory sensor of DNA damage signals that, based on its allosteric modulation by RNA, specifically binds to and inhibits CBP/p300 HAT activities on a repressed gene target, cyclin D1 (CCND1). Recruitment of TLS to the CCND1 promoter to cause gene-specific repression is directed by single stranded, low copy number ncRNA transcripts tethered to the 5′ regulatory regions of CCND1 that are induced in response to DNA damage signals. Our data suggest that signal-induced ncRNAs localized to regulatory regions of transcription units can act cooperatively as selective ligands, recruiting and modulating the activities of distinct classes of RNA binding co-regulators in response to specific signals, providing an unexpected ncRNA/RNA-binding protein-based strategy to integrate transcriptional programs.
                Bookmark

                Author and article information

                Contributors
                llan1@mgh.harvard.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                5 June 2020
                5 June 2020
                2020
                : 11
                : 2834
                Affiliations
                [1 ]ISNI 0000 0004 1936 9000, GRID grid.21925.3d, Department of Microbiology and Molecular Genetics, , University of Pittsburgh School of Medicine, ; UPMC Hillman Cancer Center, 5117 Centre Ave., Pittsburgh, PA 15213 USA
                [2 ]ISNI 000000041936754X, GRID grid.38142.3c, Massachusetts General Hospital Cancer Center, , Harvard Medical School, ; Boston, MA 02129 USA
                [3 ]ISNI 000000041936754X, GRID grid.38142.3c, Department of Radiation Oncology, Massachusetts General Hospital, , Harvard Medical School, ; Boston, MA 02129 USA
                [4 ]ISNI 000000041936754X, GRID grid.38142.3c, Department of Pathology, Massachusetts General Hospital, , Harvard Medical School, ; Boston, MA 02115 USA
                [5 ]ISNI 000000041936754X, GRID grid.38142.3c, Department of Medicine, Massachusetts General Hospital, , Harvard Medical School, ; Boston, MA 02129 USA
                Author information
                http://orcid.org/0000-0002-8377-9712
                http://orcid.org/0000-0003-3094-1058
                http://orcid.org/0000-0003-0383-6172
                Article
                16722
                10.1038/s41467-020-16722-7
                7275041
                32503981
                8c8bfbd8-d6e3-4084-b6e2-e57bc89ce1d7
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 13 December 2019
                : 19 May 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000002, U.S. Department of Health & Human Services | National Institutes of Health (NIH);
                Award ID: GM118833
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                cancer epidemiology,homologous recombination,dna recombination,epigenetics,rna modification

                Comments

                Comment on this article